Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina

NCT ID: NCT02280850

Last Updated: 2014-11-03

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 300 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-31
• Study Completion Date: 2015-10-31

Brief Summary

Compared with placebo, assess of the efficacy and safety of Guanxin Shutong capsule to treat chronic stable angina (syndrome of blood stasis resistance), and the result will be used for the basis of later Ⅳ clinical trial.

Detailed Description

1. Procedures 1.1 Start-up stage (-14~0 Day)

1. Inquire medical history, medication use, accompanied treatment, etc;

2. Sign informed consent;

3. Measure vital signs and conduct physical examination;

4. Record symptom and signs;

5. Confirm inclusion/exclusion criteria, and put patients who meet inclusion criteria into start-up stage;

6. Record participators' history of angina pectoris and treatment, or select stable angina from outpatient service (without medicate);

7. Allocate screen number, hand out Guanxi Shutong Capsules Placebo and record card of angina/nitroglycerin used;

8. Advise patient return visit with an empty belly 2 weeks later. 1.2 Interview 1 (Baseline 0 Day)

(1) Measure vital signs; (2)Accomplish all the examination items: Blood routines, Urine routines, Stool routines + Occult blood, Hepatorenal function (AST, ALT, TBIL, ALP, γ-GT, BUN, Cr), Four coagulation tests (TT, PT, APTT, FIB), Blood fat (TC, TG, HDL-C, LDL-C), 12 leads electrocardiogram, Seattle Angina Ques-tionnaire (SAQ). Additionally, premenopausal women receive urine pregnancy test; (3) Exercise treadmill testing (ETT): around am. 10:00 (Note: Just for the patients who need ETT); (4) Record symptoms and signs ( Score of syndrome of Chinese medicine and Score of angina); (5) Randomize and allocate drug number; (6) Hand out the drugs for 2 weeks and record card of angina/nitroglycerin used; (7) Advise patient return visit 2 weeks later. 1.3 Interview 2 (14±2 Day)

1. Inquire adverse events;

2. Inquire accompanied treatment and record combined medication.

3. Measure vital signs;

4. Record symptoms and signs (Score of syndrome of Chinese medicine and Score of angina);

5. Withdraw remained drugs and box, and record card;

6. Hand out the drugs for 2 weeks and record card of angina/nitroglycerin used;

7. Advise patient return visit 2 weeks later. 1.4 Interview 3 (28±2 Day)

(1) Inquire adverse events; (2) Inquire accompanied treatment and record combined medication. (3) Measure vital signs; (4) Record symptoms and signs (Score of syndrome of Chinese medicine and Score of angina); (5) 12 leads electrocardiogram (6) Accomplish all the examination items: Blood routines, Urine routines, Stool routines + Occult blood, Hepatorenal function (AST, ALT, TBIL, ALP, γ-GT, BUN, Cr), Four coagulation tests (TT, PT, APTT, FIB), Blood fat (TC, TG, HDL-C, LDL-C), 12 leads electrocardiogram, Seattle Angina Ques-tionnaire (SAQ); (7) Exercise treadmill testing (ETT) (Note: Just for the patients who need ETT); (8) Withdraw remained drugs and box, and record card; (9) Assess compliance; (10) Summarize the clinical trial.

Conditions

Angina, Stable

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Guanxin Shutong Capsule

3 capsules once, tid, Oral Duration: 4 weeks

Group Type: EXPERIMENTAL

Guanxin Shutong Capsule

Intervention Type: DRUG

3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.

nitroglycerine

Intervention Type: DRUG

Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.

The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts.

Placebo Capsule

Placebo capsule and Guanxin Shutong Capsule the same appearance are made by SHAANXI BUCHANG PHARMACEUTICAL CO.,LTD.

3 capsules once, tid, Oral Duration: 4 weeks

Group Type: PLACEBO_COMPARATOR

Placebo Capsule

Intervention Type: DRUG

3 capsules three times a day; Duration: 4 weeks.

nitroglycerine

Intervention Type: DRUG

Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.

The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts.

Interventions

Guanxin Shutong Capsule

3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention Type: DRUG

Placebo Capsule

3 capsules three times a day; Duration: 4 weeks.

Intervention Type: DRUG

nitroglycerine

Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.

The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Symptom of chronic stable angina is sustained for 3 months or over 3 months (typical symptoms of myocardial ischemia occurred at least 2 times in the latest week, and angina type is stable angina (Canada CCS class Ⅰ、Ⅱ or Ⅲ);
• Blood stasis resistance on traditional Chinese medicine syndrome differentiation;
• Patients who meet the following any situation:

1. had coronary angiography and verified a least one main branch of coronary stenosis ≥50%;

2. have typical angina symptom, and also have positive ETT result or CTA shows at least one main branch of coronary stenosis ≥50%;

3. had history of myocardial infarct (at least 6 months).

• Written informed consent.

Exclusion Criteria

• Acute coronary syndrome or highly suspected acute coronary syndrome;
• Variant angina or unstable angina;
• Myocardial infarction within the past 6 months;
• Left main disease and without revascularization was verified through angiography or CTA;
• Moderate to severe aortic stenosis, hypertrophic Obstructive Cardiomyopathy or congestive heart-failure (NYHA class Ⅲ-Ⅳ);
• Patients who were received PCI/CABG within 1 year;
• Patients who are poor control of high blood pressure (SBP>170mmHg, or DBP>100mmHg);
• Patients who have hypotension (SBP<90mmHg, DBP<60mmHg) or had orthostatic hypotension;
• ECG shows complete left bundle branch block, pre-excitation syndrome, left ventricular hypertrophy or pacemaker rhythm;
• Hypohepatia (ALT or bilirubin level is higher than upper limit), renal insufficiency (serum creatinine level is higher than upper limit);
• Active peptic ulcer or skin ulcer;
• Diagnosed chest pain caused by severe neurosis, menopausal syndrome, hyperthyroidism, cervical spondylosis, gallbladder-cardiac syndrome, gastroesophageal reflux, esophageal hiatus hernia or in aortic dissection;
• Patients had hematological disorder, specific bleeding or warfarin caused bleeding;
• Drug abuser, patients with history of alcoholism in the past 2 years or dependency to known drugs;
• Psychopath;
• Patients who can't compelet exercise test (note: just for partial patients who need to complete exercise test);
• Pregnancy or lactation;
• Patients who are known or suspected hypersensitive to the study medicine or allergic constitution;
• Patients who were received big surgery within 4 weeks or participated in other clinical trials within 3 months.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shaanxi Buchang Pharmaceutical Co., Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lv Shuzheng

Role: PRINCIPAL_INVESTIGATOR

Beijing Anzhen Hospital

Zhang Yan

Role: PRINCIPAL_INVESTIGATOR

The Affiliated Hospital of Liaoning Hospital of Traditional Chinese Medicine

Chen Bojun

Role: PRINCIPAL_INVESTIGATOR

The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

Luo Wei

Role: PRINCIPAL_INVESTIGATOR

Xuzhou Central Hospital

Jiang Binghua

Role: PRINCIPAL_INVESTIGATOR

Shandong University of Traditional Chinese Medicine

Zhang Zhenxian

Role: PRINCIPAL_INVESTIGATOR

Luohe Hospital of Traditional Chinese Medicine

Xing Yanjun

Role: PRINCIPAL_INVESTIGATOR

First Hospital of Shijiazhuang City

Locations

The General Hospital of Shenyang Military Region

Shenyang, Liaoning, China

Countries

China

Central Contacts

Han Yaling, Academician

Role: CONTACT

guanxinshutong@126.com

+86-24-28856123

Facility Contacts

Han Yaling, Academician

Role: primary

guanxinshutong@126.com

+86-24-28856123

References

Li Y, Zhang L, Lv S, Wang X, Zhang J, Tian X, Zhang Y, Chen B, Liu D, Yang J, Dong P, Xu Y, Song Y, Shi J, Li L, Wang X, Han Y. Efficacy and safety of oral Guanxinshutong capsules in patients with stable angina pectoris in China: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial. BMC Complement Altern Med. 2019 Dec 11;19(1):363. doi: 10.1186/s12906-019-2778-z.

Reference Type: DERIVED

PMID: 31829173 (View on PubMed)

Other Identifiers

YL-CTP-Z20020055

Identifier Type: -

Identifier Source: org_study_id